Developer docs
API playgroundTry for free, no card

Search company profiles

LifeMD

Full company profile

uuid00000je

Namestring
LifeMD
Legal namestring
LifeMD, Inc.
Websiteurl
lifemd.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

LifeMD, Inc. (NASDAQ: LFMD) is a publicly traded direct-to-consumer telehealth platform founded in 2013 and headquartered in New York City, operating a 50-state virtual care network organized around five vertical programs: weight management (with branded GLP-1 medications Wegovy, Zepbound, Ozempic, and Eli Lilly's oral Foundayo), women's health (hormone replacement therapy, menopause care, bone density), mental health, cardiovascular care, and 24/7 urgent/primary care under the LifeMD+ subscription. The platform is delivered through a proprietary technology stack combining video and message-based consultations, an affiliated medical group licensed across all 50 states, electronic health records, AI-assisted clinical documentation, and a vertically integrated in-house pharmacy operating under FDA 503A designation with up to 5,000 prescriptions per day capacity. Sub-brands include RexMD (men's health), ShapiroMD (dermatology/hair loss), Cleared (allergy/asthma), and NAVA MD.

The business model is predominantly subscription and transaction-based, with monthly memberships starting at $149 (first month $39 introductory) plus per-prescription medication fees that range from $149/month for oral GLP-1s to $499/month for Ozempic. LifeMD accepts major PPO insurance and Medicare for qualifying services and also sells through FSA Store and HSA Store partnerships. Go-to-market relies primarily on digital advertising and social media (Instagram, TikTok, LinkedIn, X) for top-of-funnel acquisition, with growing investor-conference-led B2B outreach toward employers and health plans. Strategic supply partnerships with Novo Nordisk (Wegovy subscription, NovoCare integration) and Eli Lilly (Foundayo) provide preferential access to in-demand GLP-1 therapies, while a $20M strategic investment from Medifast (December 2023) integrated OPTAVIA coaching into the weight management offering.

Following the November 2025 divestiture of its WorkSimpli software segment, LifeMD operates as a pure-play virtual care and pharmacy platform. Reported FY2025 revenue was approximately $194 million (up ~25% YoY), with the company swinging from a $21.4 million net loss in 2024 to $14.4 million of net income in 2025; FY2026 revenue is guided at $220-230 million. Active subscribers exceeded 322,000 across GLP-1 and women's health programs as of March 2026, and lifetime patient registrations reached over 745,000. The company has raised a $50 million revolving credit facility (January 2026) to support further corporate development.

Short descriptiontext

LifeMD is a publicly traded, direct-to-consumer telehealth platform operating across all 50 U.S. states, offering subscription-based virtual care in weight management (GLP-1 medications), women's health, mental health, cardiovascular care, and 24/7 urgent/primary care, supported by an in-house 503A pharmacy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
telehealth services, virtual primary care, weight management medications, hormone replacement therapy, online psychiatry services
Industry3 codes
PRIMARYHLALAAAA
Primary Care & General Medicine Virtual Care
Healthcare & Life Sciences/Telehealth Platforms/Direct-to-Consumer Virtual Care Platforms
SECONDARYHLALADAD
Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN)
Healthcare & Life Sciences/Telehealth Platforms/Employer-Sponsored Virtual Care Platforms
SECONDARYHLALAFAK
Behavioral Health-Integrated Chronic Care (SUD comorbidity, collaborative care)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code2 codes
  • Offices of Physicians6211
  • Offices of Physicians, Mental Health Specialists621112
SIC code2 codes
  • Services-Offices & Clinics Of Doctors Of Medicine8011
  • Services-Health Services8000
Product category
Telehealth & Virtual Primary Care Services
Social media profiles4 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Telehealth Membership/Subscription
TypeSubscription Recurring
Description

Monthly membership fees starting at $149 per month (first month discounted to $39) for access to provider consultations, care coordination, and ongoing clinical support across specialty programs.

lifemd.com
2Prescription Medication Sales
TypeTransaction Fee
Description

Revenue from dispensing GLP-1 medications (Wegovy, Zepbound, Ozempic, Foundayo), hormone replacement therapies, and other prescriptions. Pricing varies from $149/month for oral GLP-1s to $499/month for Ozempic, with insurance and cash-pay options.

lifemd.com
3Clinical Consultations
TypeTransaction Fee
Description

Fees for video visits, message-based consultations, and same-day prescription refills. Urgent and primary care services available 24/7 with varying consultation fees.

lifemd.com
4Laboratory Services
TypeTransaction Fee
Description

Revenue from diagnostic lab testing including hormone panels, cholesterol panels, thyroid function, diabetes tests, and inflammation markers. Labs ordered through Quest or Labcorp with affordable pricing.

lifemd.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Marketing or Sales, Personnel, Technology or R&D, Supply Chain, Operations, Infrastructure
Pricing details5 tiers
1Weight Loss Program - GLP-1 Medications
ModelHybridBilling cadenceMonthly
Notes

Wegovy pen: starting at $199/month (new patients, without insurance). Wegovy pill: starting at $149/month. Zepbound vial: cash-pay discounts available. Ozempic: $499/month. Insurance copay: $0-$25 for commercially insured patients. Monthly program & provider fee: $149 (first month $39). Wegovy subscription program offers up to $1,200 annual savings.

lifemd.com
2Women's Health Program
ModelSubscriptionBilling cadenceMonthly
Notes

Hormone replacement therapy including estradiol patches, topical gels, vaginal inserts/rings, and micronized progesterone. Pricing varies by medication and insurance coverage. Medicare accepted for qualifying virtual primary care.

lifemd.com
3Mental Health Services
ModelSubscriptionBilling cadenceMonthly
Notes

Psychiatric care including Wellbutrin SR, Lexapro, Prozac, Buspar, Celexa, Cymbalta, Effexor, Zoloft, Paxil. Generic medications available. Affordable and accessible psychiatric care with personalized treatment plans.

lifemd.com
4LifeMD+ Urgent & Primary Care
ModelSubscriptionBilling cadenceMonthly
Notes

24/7 access to urgent and primary care with video/message-based consultations, same-day prescriptions, and routine lab testing. No insurance required. HSA & FSA eligible.

lifemd.com
5Laboratory Testing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Affordable lab testing including Diabetes Test, Heart Health Panel, Cholesterol Panel, Thyroid Function Panel, Female Hormone Panel, Inflammation Panel, Male Hormone Panel. Discounted lab prices through Quest or Labcorp.

lifemd.com
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 4 records shown
1RexMD
Description

Men's health telehealth brand offering treatments for conditions including erectile dysfunction, hair loss, and other men's health issues.

lifemd.com
+3 more records
Core offering1 text field

LifeMD operates a direct-to-consumer telehealth platform delivering virtual primary care, urgent care, and specialty programs across all 50 U.S. states. Core programs include GLP-1-based weight management (Wegovy, Zepbound, Ozempic, Foundayo), women's hormone health, mental health psychiatry, cardiovascular care, and 24/7 urgent care — supported by a vertically integrated mail-order pharmacy and AI-assisted clinical workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Average weight loss of ~33 lbs in 64-week medical study with Wegovy
+4 more records
Product overview1 text field

LifeMD is a direct-to-patient telehealth platform operating as a portfolio of brands offering virtual primary care, diagnostics, and specialized treatment across multiple verticals. The core platform provides 50-state telehealth services through a proprietary technology stack and affiliated medical groups (LifeMD Southern Patient Medical Care, P.C., LifeMD Atlantic Patient Medical Care, P.C., and others). Key products include LifeMD+ (membership-based urgent and primary care), the Weight Management Program (GLP-1 treatments including Wegovy, Zepbound, Foundayo), Women's Health Program (HRT and menopause care), Mental Health Program (psychiatric care), and Cardiovascular Health. The company also operates sub-brands including RexMD (men's health), ShapiroMD (hair loss/dermatology), Cleared (allergy/asthma), and NAVA MD. A vertically integrated pharmacy network with compounding capabilities supports medication fulfillment. The company divested its WorkSimpli software segment in late 2025 to focus purely on virtual care and pharmacy operations.

Product and service13 records
1LifeMD+ Urgent & Primary Care
CategoryUrgent & Primary Care
Description

Subscription-based membership plan providing 24/7 access to urgent and primary care via video and message-based consultations, same-day prescriptions, and routine lab testing. No insurance is required; HSA/FSA eligible. Designed for individual consumers seeking convenient access to licensed healthcare providers for common concerns like colds, flu, rashes, and prescription refills.

2Weight Management Program
CategoryWeight Management
Description

Clinician-guided GLP-1 weight loss program offering access to branded GLP-1 medications (Wegovy injectable and pill, Zepbound, Ozempic, Mounjaro, Foundayo/orforglipron), with ongoing expert clinical guidance and insurance navigation support. Pricing starts at $149/month for cash-pay options and $0–$25 copays for commercially insured patients. Includes a Wegovy subscription program offering up to $1,200 in annual savings.

3Women's Health Program
CategoryWomen's Health
Description

Personalized care program for women offering hormone replacement therapy (estradiol patches, topical gels, vaginal inserts, micronized progesterone) and lifestyle support to ease menopause symptoms, restore balance, and address bone density, metabolism, and wellness. Led by Clinical Chair Dr. Tara Scott and Clinical Lead Dr. Doug Lucas. Medicare accepted for qualifying virtual primary care services.

4Mental Health Program
CategoryMental Health
Description

Affordable and accessible psychiatric care offering personalized treatment plans by licensed providers for conditions including anxiety, depression, performance/social anxiety, and related mental health concerns. Supports prescription medications such as Wellbutrin SR, Lexapro, Prozac, Buspar, Celexa, Cymbalta, Effexor, Zoloft, Paxil, and Inderal. Generic medications available.

5Cardiovascular Health Program
CategorySpecialty Care
Description

Virtual cardiology program connecting patients with board-certified cardiologists to manage blood pressure, cholesterol, and long-term cardiovascular risk from home, with ongoing monitoring and consultation support.

6Insomnia Treatment
CategorySpecialty Care
Description

Personalized care program for diagnosis and treatment of insomnia with ongoing provider support and prescription management where appropriate. Also offered through FSA Store and HSA Store partnerships for pre-tax benefit-eligible purchases.

7Lab Testing Services
CategoryDiagnostics
Description

Affordable lab testing and analysis available through Quest Diagnostics and Labcorp partner networks, including diabetes, heart health, cholesterol, thyroid function, female and male hormone panels, and inflammation testing. Offered as a pay-as-you-go add-on to LifeMD programs.

8RexMD
CategoryMen's Health
Description

Men's virtual pharmacy and telehealth sub-brand offering discreet access to treatments for men's health conditions including erectile dysfunction and hair loss.

9ShapiroMD
CategoryDermatology
Description

Telehealth sub-brand focused on hair loss and dermatological treatments.

10Cleared
CategoryAllergy & Asthma
Description

Allergy and asthma telehealth platform providing allergy and asthma care services, acquired by LifeMD in January 2022.

11NAVA MD
CategoryHealth & Wellness
Description

Health and wellness brand operating under the LifeMD portfolio.

12LifeMD Affiliated Pharmacy (Mail-Order)
CategoryMail-Order Pharmacy
Description

In-house mail-order pharmacy network with capacity for up to 5,000 prescriptions per day, operating under FDA 503A non-sterile compounding designation, licensed in 13 states with planned expansion to all 50 states within 12 months. Supports dispensing of branded GLP-1 medications, hormone therapies, mental health prescriptions, and custom-compounded medications directly to LifeMD patients.

13Non-Sterile Compounding Pharmacy Services
CategoryCompounding Pharmacy
Description

Advanced non-sterile compounding capabilities for oral and topical medications, enabling customized medications including allergen-free and combination products not commercially available, dispensed through the LifeMD affiliated pharmacy network.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-10
Description

Partnership to offer Eli Lilly's FDA-approved weight loss drug Foundayo (orforglipron) through LifeMD's platform. Following FDA approval on April 1, 2026, Foundayo became available to eligible patients in the United States through LifeMD's weight management program, expanding access to oral GLP-1 therapies.

2Dr. Tara Scott
Strategic tierMinorTypeOthersAnnounced on2025-10-22
Description

Dr. Tara Scott appointed as Ambassador and Clinical Advisor for LifeMD's Women's Health Program, focusing on menopause, hormonal balance, and long-term wellness. Role guides company outreach, education, and program development for underserved women's health needs.

globenewswire.com
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-09
Description

Collaboration to offer sleep treatments via FSA Store and HSA Store, expanding access to LifeMD services through employer-sponsored pre-tax healthcare benefit platforms. Partnership also includes weight management medications.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-22
Description

Collaboration to launch $299 introductory bundle for self-pay patients prescribed Wegovy. Partnership expanded to include Wegovy subscription program offering up to $1,200 in annual savings, NovoCare Pharmacy integration for medication fulfillment, and availability of Wegovy pill. Deep collaboration covering both injectable and oral GLP-1 medications across all 50 states.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-29
Description

Acquisition of assets from Optimal Human Health MD to expand into the women's health market. Deal brought on board a team of nurse practitioners, registered dietitians, patient care staff, and founder Dr. Doug Lucas (specialist in osteoporosis reversal and hormone optimization), establishing clinical foundation for virtual women's health program.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-13
Description

Strategic collaboration involving $20 million investment from Medifast ($10 million support payment and $10 million stock purchase) to integrate Medifast's OPTAVIA coach-guided health program with LifeMD's telehealth platform. Alliance aims to offer comprehensive weight management solutions combining clinical care with lifestyle coaching, targeting a market projected to reach $100 billion by 2030.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-12
Description

Acquisition of allergy telehealth platform Cleared as announced in regulatory filing. Aimed at enhancing LifeMD's telehealth service offerings with allergy and asthma care capabilities.

8NovoCare Pharmacy
Strategic tierCoreTypeTechnology or Integration
Description

Integration with Novo Nordisk's NovoCare Pharmacy for GLP-1 medication fulfillment, enabling seamless prescription processing and home delivery of Wegovy and other Novo medications.

lifemd.com
Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1Ro
TypeDirect peer
Description

DTC telehealth company offering weight management (GLP-1s including branded and compounded), men's health, women's health, fertility, and smoking cessation. Closely comparable to LifeMD in business model, product mix, and patient acquisition via digital marketing.

TypeBroad incumbent
Description

Enterprise telehealth infrastructure and virtual care platform serving health systems, insurers and employers. Overlaps with LifeMD in primary and behavioral virtual care but operates more as a B2B technology layer than a consumer brand.

TypeBroad incumbent
Description

Large incumbent virtual care platform serving employers, health plans and providers with general medical, mental health (BetterHelp) and chronic condition management. Broader and more B2B-oriented than LifeMD, but overlapping in DTC and chronic-care telehealth.

TypeDirect peer
Description

Largest direct-to-consumer telehealth competitor offering weight loss (including compounded GLP-1s), men's health, women's health, mental health and primary care on a subscription model. Operates with a similar cash-pay, vertically-integrated online clinic model targeting the same consumer demographic as LifeMD.

TypeDirect peer
Description

DTC telehealth and in-person marketplace offering weight loss (GLP-1s), primary care, mental health and specialty care on a cash-pay basis. Comparable direct-to-consumer model and product portfolio, particularly for GLP-1 weight management.

6Done Global
TypeEmerging player
Description

Direct-to-consumer telehealth platform focused on ADHD and mental health treatment, including controlled-substance prescribing. Comparable in telehealth delivery model and consumer marketing approach but narrower in clinical scope.

TypeEmerging player
Description

Subscription-based mental health telehealth platform providing therapy, counseling and medication management. Overlaps with LifeMD's Mental Health Program in care delivery and subscription pricing model.

TypeEmerging player
Description

Virtual care platform for women's and family health, including fertility, pregnancy, postpartum and menopause care. Comparable to LifeMD's Women's Health Program in target demographic and virtual care delivery.

TypeDirect peer
Description

Subscription-based weight management platform that has expanded into telehealth and GLP-1 prescribing through its Sequence and Clinic programs. Direct overlap with LifeMD's Weight Management Program in target customer and category.

10Noom
TypeEmerging player
Description

Digital health platform combining behavior change coaching with telehealth and access to GLP-1 medications. Comparable to LifeMD in weight management focus and consumer subscription model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LifeMD

Telehealth & Virtual Primary Care Serviceslifemd.com

LifeMD is a publicly traded, direct-to-consumer telehealth platform operating across all 50 U.S. states, offering subscription-based virtual care in weight management (GLP-1 medications), women's health, mental health, cardiovascular care, and 24/7 urgent/primary care, supported by an in-house 503A pharmacy.

What LifeMD does

LifeMD, Inc. (NASDAQ: LFMD) is a publicly traded direct-to-consumer telehealth platform founded in 2013 and headquartered in New York City, operating a 50-state virtual care network organized around five vertical programs: weight management (with branded GLP-1 medications Wegovy, Zepbound, Ozempic, and Eli Lilly's oral Foundayo), women's health (hormone replacement therapy, menopause care, bone density), mental health, cardiovascular care, and 24/7 urgent/primary care under the LifeMD+ subscription. The platform is delivered through a proprietary technology stack combining video and message-based consultations, an affiliated medical group licensed across all 50 states, electronic health records, AI-assisted clinical documentation, and a vertically integrated in-house pharmacy operating under FDA 503A designation with up to 5,000 prescriptions per day capacity. Sub-brands include RexMD (men's health), ShapiroMD (dermatology/hair loss), Cleared (allergy/asthma), and NAVA MD.

The business model is predominantly subscription and transaction-based, with monthly memberships starting at $149 (first month $39 introductory) plus per-prescription medication fees that range from $149/month for oral GLP-1s to $499/month for Ozempic. LifeMD accepts major PPO insurance and Medicare for qualifying services and also sells through FSA Store and HSA Store partnerships. Go-to-market relies primarily on digital advertising and social media (Instagram, TikTok, LinkedIn, X) for top-of-funnel acquisition, with growing investor-conference-led B2B outreach toward employers and health plans. Strategic supply partnerships with Novo Nordisk (Wegovy subscription, NovoCare integration) and Eli Lilly (Foundayo) provide preferential access to in-demand GLP-1 therapies, while a $20M strategic investment from Medifast (December 2023) integrated OPTAVIA coaching into the weight management offering.

Following the November 2025 divestiture of its WorkSimpli software segment, LifeMD operates as a pure-play virtual care and pharmacy platform. Reported FY2025 revenue was approximately $194 million (up ~25% YoY), with the company swinging from a $21.4 million net loss in 2024 to $14.4 million of net income in 2025; FY2026 revenue is guided at $220-230 million. Active subscribers exceeded 322,000 across GLP-1 and women's health programs as of March 2026, and lifetime patient registrations reached over 745,000. The company has raised a $50 million revolving credit facility (January 2026) to support further corporate development.

LifeMD firmographics

Firmographics
Name
LifeMD
Legal name
LifeMD, Inc.
Website
https://lifemd.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
251–500 employees
Short description
LifeMD is a publicly traded, direct-to-consumer telehealth platform operating across all 50 U.S. states, offering subscription-based virtual care in weight management (GLP-1 medications), women's health, mental health, cardiovascular care, and 24/7 urgent/primary care, supported by an in-house 503A pharmacy.
Ownership category
akta.pro rank

LifeMD industry classification

Industry
Product category
Telehealth & Virtual Primary Care Services
NAICS
Offices of Physicians (6211), Offices of Physicians, Mental Health Specialists (621112)
SIC
Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)
akta.pro industry
PRIMARYHLALAAAA
Primary Care & General Medicine Virtual Care
Healthcare & Life Sciences/Telehealth Platforms/Direct-to-Consumer Virtual Care Platforms
SECONDARYHLALADAD
Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN)
Healthcare & Life Sciences/Telehealth Platforms/Employer-Sponsored Virtual Care Platforms
SECONDARYHLALAFAK
Behavioral Health-Integrated Chronic Care (SUD comorbidity, collaborative care)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Telehealth services
  • Virtual primary care
  • Weight management medications
  • Hormone replacement therapy
  • Online psychiatry services

Where LifeMD is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

LifeMD business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Marketing or Sales, Personnel, Technology or R&D, Supply Chain, Operations, Infrastructure

Revenue model

  1. Telehealth Membership/Subscription: Monthly membership fees starting at $149 per month (first month discounted to $39) for access to provider consultations, care coordination, and ongoing clinical support across specialty programs.
  2. Prescription Medication Sales: Revenue from dispensing GLP-1 medications (Wegovy, Zepbound, Ozempic, Foundayo), hormone replacement therapies, and other prescriptions. Pricing varies from $149/month for oral GLP-1s to $499/month for Ozempic, with insurance and cash-pay options.
  3. Clinical Consultations: Fees for video visits, message-based consultations, and same-day prescription refills. Urgent and primary care services available 24/7 with varying consultation fees.
  4. Laboratory Services: Revenue from diagnostic lab testing including hormone panels, cholesterol panels, thyroid function, diabetes tests, and inflammation markers. Labs ordered through Quest or Labcorp with affordable pricing.

Pricing tiers

ModelBillingPrice
HybridMonthlyWeight Loss Program - GLP-1 Medications
SubscriptionMonthlyWomen's Health Program
SubscriptionMonthlyMental Health Services
SubscriptionMonthlyLifeMD+ Urgent & Primary Care
Unit PricingPay-as-you-goLaboratory Testing

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

LifeMD product offering

Product offering

Core offering

LifeMD operates a direct-to-consumer telehealth platform delivering virtual primary care, urgent care, and specialty programs across all 50 U.S. states. Core programs include GLP-1-based weight management (Wegovy, Zepbound, Ozempic, Foundayo), women's hormone health, mental health psychiatry, cardiovascular care, and 24/7 urgent care — supported by a vertically integrated mail-order pharmacy and AI-assisted clinical workflows.

Product overview

LifeMD is a direct-to-patient telehealth platform operating as a portfolio of brands offering virtual primary care, diagnostics, and specialized treatment across multiple verticals. The core platform provides 50-state telehealth services through a proprietary technology stack and affiliated medical groups (LifeMD Southern Patient Medical Care, P.C., LifeMD Atlantic Patient Medical Care, P.C., and others). Key products include LifeMD+ (membership-based urgent and primary care), the Weight Management Program (GLP-1 treatments including Wegovy, Zepbound, Foundayo), Women's Health Program (HRT and menopause care), Mental Health Program (psychiatric care), and Cardiovascular Health. The company also operates sub-brands including RexMD (men's health), ShapiroMD (hair loss/dermatology), Cleared (allergy/asthma), and NAVA MD. A vertically integrated pharmacy network with compounding capabilities supports medication fulfillment. The company divested its WorkSimpli software segment in late 2025 to focus purely on virtual care and pharmacy operations.

Differentiator

Problem solved

Functional benefit

Brands

  • RexMD: Men's health telehealth brand offering treatments for conditions including erectile dysfunction, hair loss, and other men's health issues.
  • ShapiroMD
  • Cleared
  • NAVA MD

Products and services

  • LifeMD+ Urgent & Primary Care Subscription-based membership plan providing 24/7 access to urgent and primary care via video and message-based consultations, same-day prescriptions, and routine lab testing. No insurance is required; HSA/FSA eligible. Designed for individual consumers seeking convenient access to licensed healthcare providers for common concerns like colds, flu, rashes, and prescription refills.
  • Weight Management Program Clinician-guided GLP-1 weight loss program offering access to branded GLP-1 medications (Wegovy injectable and pill, Zepbound, Ozempic, Mounjaro, Foundayo/orforglipron), with ongoing expert clinical guidance and insurance navigation support. Pricing starts at $149/month for cash-pay options and $0–$25 copays for commercially insured patients. Includes a Wegovy subscription program offering up to $1,200 in annual savings.
  • Women's Health Program Personalized care program for women offering hormone replacement therapy (estradiol patches, topical gels, vaginal inserts, micronized progesterone) and lifestyle support to ease menopause symptoms, restore balance, and address bone density, metabolism, and wellness. Led by Clinical Chair Dr. Tara Scott and Clinical Lead Dr. Doug Lucas. Medicare accepted for qualifying virtual primary care services.
  • Mental Health Program Affordable and accessible psychiatric care offering personalized treatment plans by licensed providers for conditions including anxiety, depression, performance/social anxiety, and related mental health concerns. Supports prescription medications such as Wellbutrin SR, Lexapro, Prozac, Buspar, Celexa, Cymbalta, Effexor, Zoloft, Paxil, and Inderal. Generic medications available.
  • Cardiovascular Health Program Virtual cardiology program connecting patients with board-certified cardiologists to manage blood pressure, cholesterol, and long-term cardiovascular risk from home, with ongoing monitoring and consultation support.
  • Insomnia Treatment Personalized care program for diagnosis and treatment of insomnia with ongoing provider support and prescription management where appropriate. Also offered through FSA Store and HSA Store partnerships for pre-tax benefit-eligible purchases.
  • Lab Testing Services Affordable lab testing and analysis available through Quest Diagnostics and Labcorp partner networks, including diabetes, heart health, cholesterol, thyroid function, female and male hormone panels, and inflammation testing. Offered as a pay-as-you-go add-on to LifeMD programs.
  • RexMD Men's virtual pharmacy and telehealth sub-brand offering discreet access to treatments for men's health conditions including erectile dysfunction and hair loss.
  • ShapiroMD Telehealth sub-brand focused on hair loss and dermatological treatments.
  • Cleared Allergy and asthma telehealth platform providing allergy and asthma care services, acquired by LifeMD in January 2022.
  • NAVA MD Health and wellness brand operating under the LifeMD portfolio.
  • LifeMD Affiliated Pharmacy (Mail-Order) In-house mail-order pharmacy network with capacity for up to 5,000 prescriptions per day, operating under FDA 503A non-sterile compounding designation, licensed in 13 states with planned expansion to all 50 states within 12 months. Supports dispensing of branded GLP-1 medications, hormone therapies, mental health prescriptions, and custom-compounded medications directly to LifeMD patients.
  • Non-Sterile Compounding Pharmacy Services Advanced non-sterile compounding capabilities for oral and topical medications, enabling customized medications including allergen-free and combination products not commercially available, dispensed through the LifeMD affiliated pharmacy network.

Quantifiable outcome

  • Average weight loss of ~33 lbs in 64-week medical study with Wegovy
  • +4 more outcomes

Companies that use LifeMD

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles3 records

LifeMD technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability3 records

Feature4 records

LifeMD partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Eli Lilly and CompanycoreStrategic or Co-development Partner · 10 April 2026Partnership to offer Eli Lilly's FDA-approved weight loss drug Foundayo (orforglipron) through LifeMD's platform. Following FDA approval on April 1, 2026, Foundayo became available to eligible patients in the United States through LifeMD's weight management program, expanding access to oral GLP-1 therapies.
  • Dr. Tara ScottminorOthers · 22 October 2025Dr. Tara Scott appointed as Ambassador and Clinical Advisor for LifeMD's Women's Health Program, focusing on menopause, hormonal balance, and long-term wellness. Role guides company outreach, education, and program development for underserved women's health needs.
  • Health-E CommerceminorChannel Partner/ Reseller/ Distributor · 9 June 2025Collaboration to offer sleep treatments via FSA Store and HSA Store, expanding access to LifeMD services through employer-sponsored pre-tax healthcare benefit platforms. Partnership also includes weight management medications.
  • Novo NordiskcoreStrategic or Co-development Partner · 22 May 2025Collaboration to launch $299 introductory bundle for self-pay patients prescribed Wegovy. Partnership expanded to include Wegovy subscription program offering up to $1,200 in annual savings, NovoCare Pharmacy integration for medication fulfillment, and availability of Wegovy pill. Deep collaboration covering both injectable and oral GLP-1 medications across all 50 states.
  • Optimal Human Health MDcoreStrategic or Co-development Partner · 29 April 2025Acquisition of assets from Optimal Human Health MD to expand into the women's health market. Deal brought on board a team of nurse practitioners, registered dietitians, patient care staff, and founder Dr. Doug Lucas (specialist in osteoporosis reversal and hormone optimization), establishing clinical foundation for virtual women's health program.
  • MedifastcoreStrategic or Co-development Partner · 13 December 2023Strategic collaboration involving $20 million investment from Medifast ($10 million support payment and $10 million stock purchase) to integrate Medifast's OPTAVIA coach-guided health program with LifeMD's telehealth platform. Alliance aims to offer comprehensive weight management solutions combining clinical care with lifestyle coaching, targeting a market projected to reach $100 billion by 2030.
  • ClearedminorStrategic or Co-development Partner · 12 January 2022Acquisition of allergy telehealth platform Cleared as announced in regulatory filing. Aimed at enhancing LifeMD's telehealth service offerings with allergy and asthma care capabilities.
  • NovoCare PharmacycoreTechnology or IntegrationIntegration with Novo Nordisk's NovoCare Pharmacy for GLP-1 medication fulfillment, enabling seamless prescription processing and home delivery of Wegovy and other Novo medications.

Scale indicators15 records

Recent moves11 records

Expansion highlights7 records

LifeMD competitors and assessment

Company assessment

Direct peers

  • Ro: DTC telehealth company offering weight management (GLP-1s including branded and compounded), men's health, women's health, fertility, and smoking cessation. Closely comparable to LifeMD in business model, product mix, and patient acquisition via digital marketing.
  • Hims & Hers Health: Largest direct-to-consumer telehealth competitor offering weight loss (including compounded GLP-1s), men's health, women's health, mental health and primary care on a subscription model. Operates with a similar cash-pay, vertically-integrated online clinic model targeting the same consumer demographic as LifeMD.
  • Sesame: DTC telehealth and in-person marketplace offering weight loss (GLP-1s), primary care, mental health and specialty care on a cash-pay basis. Comparable direct-to-consumer model and product portfolio, particularly for GLP-1 weight management.
  • WeightWatchers (WW): Subscription-based weight management platform that has expanded into telehealth and GLP-1 prescribing through its Sequence and Clinic programs. Direct overlap with LifeMD's Weight Management Program in target customer and category.

Broad incumbents

  • Amwell: Enterprise telehealth infrastructure and virtual care platform serving health systems, insurers and employers. Overlaps with LifeMD in primary and behavioral virtual care but operates more as a B2B technology layer than a consumer brand.
  • Teladoc Health: Large incumbent virtual care platform serving employers, health plans and providers with general medical, mental health (BetterHelp) and chronic condition management. Broader and more B2B-oriented than LifeMD, but overlapping in DTC and chronic-care telehealth.

Emerging players

  • Done Global: Direct-to-consumer telehealth platform focused on ADHD and mental health treatment, including controlled-substance prescribing. Comparable in telehealth delivery model and consumer marketing approach but narrower in clinical scope.
  • Cerebral: Subscription-based mental health telehealth platform providing therapy, counseling and medication management. Overlaps with LifeMD's Mental Health Program in care delivery and subscription pricing model.
  • Maven Clinic: Virtual care platform for women's and family health, including fertility, pregnancy, postpartum and menopause care. Comparable to LifeMD's Women's Health Program in target demographic and virtual care delivery.
  • Noom: Digital health platform combining behavior change coaching with telehealth and access to GLP-1 medications. Comparable to LifeMD in weight management focus and consumer subscription model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

LifeMD social profiles

Digital presence

LifeMD compliance and trust

Trust signal

Compliance3 records

LifeMD financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LifeMD leadership team

Management profile

Number of profiles

Profiles8 records

LifeMD subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

LifeMD funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LifeMD M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LifeMD

What does LifeMD do?

LifeMD operates a direct-to-consumer telehealth platform delivering virtual primary care, urgent care, and specialty programs across all 50 U.S. states. Core programs include GLP-1-based weight management (Wegovy, Zepbound, Ozempic, Foundayo), women's hormone health, mental health psychiatry, cardiovascular care, and 24/7 urgent care — supported by a vertically integrated mail-order pharmacy and AI-assisted clinical workflows.

Is LifeMD a public or private company?

LifeMD is a public company. It is classified as public and is currently operating.

When was LifeMD founded?

LifeMD was founded in 2013. It employs 251 to 500 people.

Where is LifeMD based?

LifeMD is headquartered in New York, United States, in the North America region.

How does LifeMD make money?

Four revenue lines are on record. Telehealth Membership/Subscription is the primary driver. The others are prescription Medication Sales, clinical Consultations and laboratory Services.

Who are LifeMD's main competitors?

Direct peers on record are Ro, Hims & Hers Health, Sesame and WeightWatchers (WW). Broad incumbents are Amwell and Teladoc Health. Emerging players are Done Global, Cerebral, Maven Clinic and Noom.

Does LifeMD have an API?

No public API is recorded for LifeMD.

What industry is LifeMD in?

LifeMD's product category is Telehealth & Virtual Primary Care Services. Its primary akta.pro industry code is HLALAAAA, Primary Care & General Medicine Virtual Care, with a secondary code of HLALADAD, Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN). Its NAICS code is 6211 and its SIC code is 8011.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewHC Wainwright & Co. maintains LifeMD at Buy, lowers price target to $6 from $9HC Wainwright & Co. maintained LifeMD at Buy and lowered its price target to $6 from $9, a 33.3% decrease. The target implies an upside of 234.3% from the Nov 17 close of $1.79.The future of tradingLifeMD, Inc. (LFMD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the InvestigationBronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of LifeMD, Inc. purchasers. The investigation follows a November 9, 2026 Form 10-Q disclosure of corrections to historical financial statements, which caused the stock to fall as much as 14.56% intraday. The firm represents investors on a contingency fee basis.NasdaqLifeMD: 3 Key Takeaways for Long-Term InvestorsLifeMD announced on its Q3 2026 earnings call a shift to direct pharmacy distribution of branded GLP-1 weight-loss drugs with Eli Lilly and Novo Nordisk. It also partnered with AT&T to give 100 million customers free access, and lowered introductory prices from $75 to $39, raising multi-month plan adoption from 25% to 85%.The Motley FoolLifeMD: 3 Key Takeaways for Long-Term InvestorsLifeMD announced on its Q3 2026 earnings call a shift to direct pharmacy distribution of branded GLP-1 weight-loss drugs, partnering with Eli Lilly and Novo Nordisk. It also launched an AT&T enterprise distribution channel and cut introductory prices from $75 to $39, reducing customer acquisition cost by 40% and raising multi-month plan selection to 85%.TradingViewLifeMD, Inc. Stock 12‑Month Price Target Raised to $7.5, Implies 242% UpsideAnalysts' average price target for LifeMD, Inc. rose to $7.5 from $7.12, implying about 242% upside from the Nov. 13 closing price. The consensus remains a Buy across six analysts, with forecasts ranging from $5 to $9 per share.TradingViewLifeMD, Inc. Stock 12‑Month Price Target Cut to $8, Implies 383% UpsideAnalysts' average price target for LifeMD, Inc. fell from $8.12 to $8, with forecasts ranging from $5 to $15 per share. Based on the Nov. 12 closing price, the updated target implies about 383% upside. The consensus rating remains Buy across 8 analysts.The Motley FoolLifeMD (LFMD) Q3 2026 Earnings Call TranscriptLifeMD reported Q3 2026 revenue of $44.6 million, down 7% year-over-year and missing guidance due to delays in branded GLP-1 fulfillment. Adjusted EBITDA was negative $0.4 million, and the company revised its full-year revenue run rate to $200 million from $250 million. Management guided Q4 revenue to $46–49 million and full-year revenue to $188–191 million.Seeking AlphaLifeMD, Inc. (LFMD) Q3 2026 Earnings Call TranscriptLifeMD's Q3 2026 earnings call was held on November 12, 2026, with CEO Justin Schreiber and CFO Atul Kavthekar. The call included management's prepared remarks and a Q&A session, with forward-looking statements and non-GAAP measures discussed.Quiver QuantitativeLIFEMD ($LFMD) Releases Q3 2026 Earnings | LFMD Stock NewsLIFEMD reported Q3 2026 earnings of -$0.11 per share, beating estimates by $0.03, but revenue of $44.63M missed by $5.23M. The stock fell 10.57% after market close, and 45 institutional investors added shares while 59 reduced positions.Investing.comWhy is LifeMD stock sliding today?LifeMD's stock fell 9.4% after-hours following Q3 2026 results that missed revenue expectations and a full-year outlook cut. Quarterly revenue of $44.6 million fell 7% year over year, and the company lowered its 2026 revenue guidance to $188–191 million. A securities investigation over accounting corrections also weighed on sentiment.